Qiagen Plans Mid-Year Launch of Clinical NGS Platform; Says Gene Panels will Complement RT-PCR Tests | GenomeWeb

This article was originally published Jan. 8.

SAN FRANCISCO — Qiagen's CEO Peer Schatz said this week during a presentation at the JP Morgan Healthcare conference here that the company is on track to launch a clinically oriented next-gen sequencing system in the middle of this year.

Schatz added, however, that the platform is "simply a part of a complete solution" that involves leveraging Qiagen's broad array of tests, whether based on real-time PCR or sequencing, and "making that the complete solution for molecular diagnostics and biomedical research."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.